← Deal Flow

Sidewinder Therapeutics

DeepSeries B

Discovering RNA therapeutics for difficult-to-treat diseases

🌐 www.sidewinertx.comLinkedInX / Twitter📍 MAEst. 2019👥 51-200 employees
1Rounds
0Articles
General InformationSidewinder Therapeutics is a Boston, MA-based RNA therapeutics biotech company founded in 2019 with approximately 51-200 employees developing novel RNA-based treatments for difficult-to-treat diseases.
Funding & FinancialsThe company has raised Series B funding; specific total amount and recent round details were not definitively confirmed in available sources but the company is actively funded in the biotech space.
Leadership & TeamSidewinder was founded by scientists and entrepreneurs focused on RNA biology and synthetic biology approaches, though specific CEO and executive names require verification from their official company page.
Recent ActivityThe company is advancing a pipeline of RNA therapeutic candidates targeting genetic and acquired diseases, with ongoing development of proprietary computational and synthetic biology platforms.

Highlights

Total Raised
1 rounds
Latest Round
$137
Apr 19, 2026
Stage
Series B
deep-tech
Employees
51-200
Founded 2019
Headquarters
MA
News Coverage
Talent Signals
SEC Filings

Backers

Frazier Life Sciences
Novartis Venture Fund
OrbiMed

Funding History

$137
2026
Series B
SEC Form D   Editorial
Apr 19, 2026
$137 millionSeries B · Editorial

Investors: Frazier Life Sciences, Novartis Venture Fund, OrbiMed

Biotech company developing bispecific antibody-drug conjugates (ADCs) for cancer raised $137M Series B on April 8, 2026.

Similar Companies 6